Savara amends bylaws to update stockholder proposal and director nomination procedures

Savara Inc

Added updated procedures for stockholder proposals and director nominations, including additional information requirements.
Requires nominating stockholders to comply with Rule 14a-19 universal proxy rules and use a proxy card color other than white.
Revised director removal provision: directors may be removed with or without cause by majority vote.
Added emergency bylaw provision for board quorum during emergencies; updated electronic transmission notice provisions.
Amendments also reflect name change from Mast Therapeutics to Savara Inc. and conform to recent DGCL changes.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Savara Inc: Adopted Amended and Restated Bylaws with updates including stockholder proposal procedures, director nomination requirements, universal proxy rules, electronic notice, name change, written consent, director removal, adjournment procedures, and emergency bylaws (effective 2023-03-28).

Change: bylaw amendment
Effective: 2023-03-28

Exact text from the filing

On March 28, 2023, in connection with a periodic review of the Composite Amended and Restated Bylaws, as amended, of Savara Inc. (“Savara”), the Board of Directors (the “Board”) of Savara adopted and approved Savara’s Amended and Restated Bylaws (the “Amended Bylaws”), which became immediately effective.

View on SEC.gov

Browse all governance changes →

Savara Inc filing history →

Source: SEC EDGAR

accession 0001193125-23-085762

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.